- Home
- ICUCW vs GNLX Comparison
ICUCW vs GNLX Comparison
Compare ICUCW & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICUCW
- GNLX
- Stock Information
- Founded
- ICUCW N/A
- GNLX 2001
- Country
- ICUCW United States
- GNLX United States
- Employees
- ICUCW 19
- GNLX N/A
- Industry
- ICUCW Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- ICUCW Health Care
- GNLX Health Care
- Exchange
- ICUCW Nasdaq
- GNLX Nasdaq
- Market Cap
- ICUCW N/A
- GNLX 112.8M
- IPO Year
- ICUCW 2021
- GNLX 2023
- Fundamental
- Price
- ICUCW N/A
- GNLX $3.09
- Analyst Decision
- ICUCW
- GNLX Strong Buy
- Analyst Count
- ICUCW 0
- GNLX 4
- Target Price
- ICUCW N/A
- GNLX $17.75
- AVG Volume (30 Days)
- ICUCW N/A
- GNLX 137.5K
- Earning Date
- ICUCW N/A
- GNLX 08-13-2025
- Dividend Yield
- ICUCW N/A
- GNLX N/A
- EPS Growth
- ICUCW N/A
- GNLX N/A
- EPS
- ICUCW N/A
- GNLX N/A
- Revenue
- ICUCW N/A
- GNLX N/A
- Revenue This Year
- ICUCW N/A
- GNLX N/A
- Revenue Next Year
- ICUCW N/A
- GNLX N/A
- P/E Ratio
- ICUCW N/A
- GNLX N/A
- Revenue Growth
- ICUCW N/A
- GNLX N/A
- 52 Week Low
- ICUCW N/A
- GNLX $1.60
- 52 Week High
- ICUCW N/A
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- ICUCW N/A
- GNLX 56.10
- Support Level
- ICUCW N/A
- GNLX $2.75
- Resistance Level
- ICUCW N/A
- GNLX $3.17
- Average True Range (ATR)
- ICUCW 0.00
- GNLX 0.24
- MACD
- ICUCW 0.00
- GNLX -0.00
- Stochastic Oscillator
- ICUCW 0.00
- GNLX 56.94
About ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.